Crescent Biopharma, Inc. Insider Trading

CBIO

⊜ Compare

Last 12 months

Insiders bought $18.2M and sold $1.51M on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

+$16.7M

1 buy · 14 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 7

executives and directors

Last open-market buy

Dec 2025

Dec 4, 2025

Get an email when CBIO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 16 – 18	Joshua T Brumm Chief Executive Officer	Sold10b5-1 plan 2 parts	9,447	$16.91 average	160K	3.4%	Form 4
Sep 16 – 18	Jonathan McNeill President and COO	Sold10b5-1 plan 2 parts	4,570	$16.90 average	77K	3.3%	Form 4
Sep 16	Ryan Lynch See Remarks	Sold10b5-1 plan	240	$17.90	4K	1.7%	Form 4
Sep 16	Jan Pinkas Chief Scientific Officer	Sold10b5-1 plan	658	$17.90	12K	3.0%	Form 4
Sep 16	Ellie Eunkyung Im Chief Medical Officer	Sold10b5-1 plan	623	$17.90	11K	2.8%	Form 4
Sep 16	Richard William Scalzo Chief Financial Officer	Sold10b5-1 plan	568	$17.90	10K	2.8%	Form 4
Sep 16	Barbara Harlin Bispham See Remarks	Sold10b5-1 plan	620	$17.90	11K	3.2%	Form 4
Jul 16	Fairmount Healthcare Fund II L.p. Large holder	Bought	853,450	$14.50	$12.4M	31%	Form 4
Jun 22	Ryan Lynch See Remarks	Sold10b5-1 plan	465	$17.99	8K	3.2%	Form 4
Jun 22	Jan Pinkas Chief Scientific Officer	Sold10b5-1 plan	1,288	$17.99	23K	5.5%	Form 4
Jun 22	Richard William Scalzo Chief Financial Officer	Sold10b5-1 plan	1,112	$17.99	20K	5.2%	Form 4
Jun 22	Barbara Harlin Bispham See Remarks	Sold10b5-1 plan	1,218	$17.99	22K	5.9%	Form 4
Jun 22	Ellie Eunkyung Im Chief Medical Officer	Sold10b5-1 plan	1,219	$17.99	22K	5.2%	Form 4
Jun 22	Jonathan McNeill President and COO	Sold10b5-1 plan	20,549	$17.99	370K	13%	Form 4
Jun 22	Joshua T Brumm Chief Executive Officer	Sold10b5-1 plan	42,305	$17.99	761K	13%	Form 4
Dec 4, 2025	Peter Evan Harwin Director	Bought	1,360,000	$13.41	$18.2M	98%	Form 4

Sep 16 – 1810b5-1 plan
Joshua T Brumm
Chief Executive Officer · sold 9,447 at avg $16.91
160K
3.4% of stake
Sep 16 – 1810b5-1 plan
Jonathan McNeill
President and COO · sold 4,570 at avg $16.90
77K
3.3% of stake
Sep 1610b5-1 plan
Ryan Lynch
See Remarks · sold 240 at $17.90
4K
1.7% of stake
Sep 1610b5-1 plan
Jan Pinkas
Chief Scientific Officer · sold 658 at $17.90
12K
3.0% of stake
Sep 1610b5-1 plan
Ellie Eunkyung Im
Chief Medical Officer · sold 623 at $17.90
11K
2.8% of stake
Sep 1610b5-1 plan
Richard William Scalzo
Chief Financial Officer · sold 568 at $17.90
10K
2.8% of stake
Sep 1610b5-1 plan
Barbara Harlin Bispham
See Remarks · sold 620 at $17.90
11K
3.2% of stake
Jul 16
Fairmount Healthcare Fund II L.p.
Large holder · bought 853,450 at $14.50
$12.4M
31% of stake
Jun 2210b5-1 plan
Ryan Lynch
See Remarks · sold 465 at $17.99
8K
3.2% of stake
Jun 2210b5-1 plan
Jan Pinkas
Chief Scientific Officer · sold 1,288 at $17.99
23K
5.5% of stake
Jun 2210b5-1 plan
Richard William Scalzo
Chief Financial Officer · sold 1,112 at $17.99
20K
5.2% of stake
Jun 2210b5-1 plan
Barbara Harlin Bispham
See Remarks · sold 1,218 at $17.99
22K
5.9% of stake
Jun 2210b5-1 plan
Ellie Eunkyung Im
Chief Medical Officer · sold 1,219 at $17.99
22K
5.2% of stake
Jun 2210b5-1 plan
Jonathan McNeill
President and COO · sold 20,549 at $17.99
370K
13% of stake
Jun 2210b5-1 plan
Joshua T Brumm
Chief Executive Officer · sold 42,305 at $17.99
761K
13% of stake
Dec 4, 2025
Peter Evan Harwin
Director · bought 1,360,000 at $13.41
$18.2M
98% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CBIO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CBIO

CompareIntrinsic value

BIOABioAge Labs, Inc.

$5.95-0.17%10

ZBIOZenas BioPharma, Inc.

$28.46+0.28%10

EVMNEvommune, Inc.

$6.04+1.68%35

IRDOpus Genetics Inc.

$4.27+8.65%10

PGENPrecigen Inc.

$5.06-3.71%0

ISCOInternational Stem Cell Corporation

$0.14+0.00%29

HOOKHookipa Pharma Inc.

No recent price20

CVSICV Sciences, Inc.

$0.01-1.00%25

Held by ETFs

CBIO is in 8 US ETFs. The largest of them, with CBIO's weight in each:

Spot a number that looks wrong? Check it in CBIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CBIO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.